Trial Profile

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Ensartinib (Primary) ; Lorlatinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Carcinoma; Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Acronyms NCI-NRG ALK Protocol

Most Recent Events

03 Feb 2025 Planned End Date changed from 19 Sep 2025 to 2 Dec 2025.
16 Oct 2024 Planned End Date changed from 21 Sep 2024 to 19 Sep 2025.
05 Dec 2023 Number of treatment arms are increased from 7 to 10 by the addition of separate experimental arms for 3 mutations namely- ALK L1198F mutation, L1196 mutation and No ALK-resistance mutations.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com